

United States of America

Tuberculosis profile

Population 2016

322 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.53 (0.52–0.53)	0.16 (0.16–0.17)
Mortality (HIV+TB only)	0.086 (0.057–0.12)	0.03 (0.02–0.04)
Incidence (includes HIV+TB)	10 (8.7–12)	3.1 (2.7–3.6)
Incidence (HIV+TB only)	0.56 (0.47–0.65)	0.17 (0.15–0.2)
Incidence (MDR/RR-TB)**	0.18 (0.13–0.22)	0.05 (0.04–0.07)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.41 (0.35–0.47)	3.6 (3.1–4.1)	4 (3.4–4.6)
Males	0.46 (0.39–0.53)	5.7 (4.8–6.5)	6.1 (5.2–7.1)
Total	0.88 (0.74–1)	9.3 (7.9–11)	10 (8.7–12)

TB case notifications, 2016

Total cases notified	9 257
Total new and relapse	8 814
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	93%
- % pulmonary	79%
- % bacteriologically confirmed among pulmonary	84%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.06 (0.05–0.07)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	466	6%
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			130 (100–150)
Estimated % of TB cases with MDR/RR-TB	1.5% (1.2–1.8)	5.6% (3.2–9.1)	
% notified tested for rifampicin resistance	75%	67%	6 949
MDR/RR-TB cases tested for resistance to second-line drugs			94
Laboratory-confirmed cases		MDR/RR-TB: 113, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: 113, XDR-TB: 1	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	83%	8 953
Previously treated cases, excluding relapse, registered in 2015	77%	465
HIV-positive TB cases registered in 2015	77%	429
MDR/RR-TB cases started on second-line treatment in 2014	78%	108
XDR-TB cases started on second-line treatment in 2014	0%	2

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2017

National TB budget (US\$ millions)	142
------------------------------------	-----


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB